Corporate ActionAug 4, 2026, 07:03 AM
Attovia Therapeutics to Offer 17M Shares in IPO at $17.00/Share
AI Summary
Attovia Therapeutics, Inc. filed an S-1/A registration statement for its initial public offering, proposing to offer 17,000,000 shares of common stock at an estimated price of $17.00 per share. The company expects to raise approximately $265.1 million in net proceeds, which will be used to advance its clinical development programs for ATTO-1310, ATTO-2306, and ATTO-1091, as well as for general corporate purposes. Attovia, a clinical-stage biopharmaceutical company, reported $115.1 million in cash, cash equivalents, and marketable securities as of June 30, 2026, and has applied to list its common stock on the Nasdaq Global Market under the symbol "ATTO".
Key Highlights
- Offering 17,000,000 shares of common stock in its initial public offering.
- Estimated initial public offering price is $17.00 per share.
- Applied to list common stock on Nasdaq Global Market under symbol "ATTO".
- Estimated net proceeds from the offering are $265.1 million.
- Cash, cash equivalents, and marketable securities were $115.1 million as of June 30, 2026.
- ATTO-1310 completed Phase 1 clinical trial, with Phase 2 expected in H1 2027.
- ATTO-2306 and ATTO-1091 are in IND-enabling studies, with Phase 1 trials expected in H1 2027.
- Company incorporated on December 16, 2022, and raised $255.8 million since inception.
Price Impact
More from ATTO